report result today miss consensu sever key
metric includ revenu vs consensu
revenu segment na vs consensu emea
adjust ep modestli ahead consensu
well forecast despit
underspend vs consensu higher
expect gross margin vs consensu
strateg review potenti
upgrad stock idea despit signific
reserv valu attract earn
upward momentum given then-pend launch gener
subsequ announc compani
enter new multi-year employ agreement sever
member senior manag team disappoint
given stock under-perform
past one year two year five year period addit
despit stock perform epipen situat price collus
alleg lower earn guidanc extens advair
delay note relat parti relationship continu
concern us recent disclosur chairman paid
use compani plane us new employ
agreement seem recogn stock price perform
downgrad share market perform compani
continu perform expect believ
declin today vs reflect neg earn
report today type declin specul
previous made press potenti sale privat equiti
may re-emerg howev decid return core
belief risk outweigh valuat especi
lack outcom major announc strateg
review lead us believ strateg review go
result materi chang granular product profit
review announc sound us like someth
done could result discontinu
product line may result lower revenu growth expect
potenti shed sale
market seem reflect sentiment alreadi
will non-consensu compani continu
under-perform without strong belief catalyst
valu underappreci lower rate
market perform new price target
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
report non-gaap ep exclud one-tim item includ restructur
estim sum full-year total estim yet
adjust effect result
compani data secur llc estim reuter
chang rate market perform base expect outperform
backend load broadli disappoint lower price target
reflect termin multipl dcf valuat discount rate
exhibit result vs estim consensu
million unless otherwis note
compani file factset secur llc estim
price target
dcf-deriv price target base discount rate termin ev/ebitda multipl
risk includ gener drug market dynam like continu challeng
gener drug penetr may alreadi peak epipen concentr sale profit
govern risk sec investig lawsuit integr risk tie meda deal
rate base expect outperform back-end load
broadli disappoint believ strateg review result materi
chang market may alreadi discount sentiment see near-term catalyst
underappreci posit rate
mylan inc base canonsburg pa domicil netherland among world
largest gener pharmaceut compani engag develop licens manufactur
market distribut gener proprietari pharmaceut product primari specialti
pharma product epipen treatment acut allerg reaction
